Navigation Links
Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session

e 20 evaluable patients with measurable tumor lesions, treatment with CB7630 resulted in partial radiological responses (as measured by the RECIST criteria) in 11 patients (55%), with 7 patients demonstrating ongoing stable disease and 3 patients experienced regressing bone disease. Individual patients treated with CB7630 also experienced improvement in pain and a reduction in opioid use. Circulating tumor cells (CTC) were detected in 14 of 31 patients and changes in CTC counts were shown to correlate with changes in PSA.

Currently 27 (90%) of the 30 patients in the Phase I/II trial remain on study and continue to be treated with CB7630. Of the 15 patients in the Phase I portion of the trial, 12 patients (80%) are still receiving treatment with CB7630, with the average patient having received the drug for over 8.5 months and 4 patients having received the drug for over 12 months.

Abiraterone, an oral, irreversible CYP450c17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer patients

The Phase II trial is being conducted at numerous locations in the United States and United Kingdom. In the trial, CB7630 is administered orally, once daily, to patients with castration refractory prostate cancer who have failed treatment with first line docetaxel based chemotherapy. The oral presentation was made by Dr. Alison H. M. Reid from The Institute of Cancer Research.

To date, 19 patients have been treated in this Phase II trial, with 13 of the patients having been treated for over 3 months. Of the 19 patients who have been treated, CB7630 was well tolerated with only minimal toxicity in this post-docetaxel population. In the 13 patients who have been on study for over 3 months, 8 patients (62%) experienced confirmed declines in PSA levels of greater than 50%, with 2 of the 13 patients (15%) experiencing PSA declines of greater than 90%. All 19 patients in this trial are still receiving treatment with CB7
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
(Date:2/27/2015)... CHAPEL HILL, N.C. , Feb. 27, 2015 /PRNewswire/ ... evolved over the past decade but one thing hasn,t ... for MSLs to build relationships with Key Opinion Leaders. ... are recognized as the most valuable type of interaction, ... external limits on their KOL interactions. This is just ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... 2011 Verilogue, the physician-patient dialogue expert, today ... initiatives, including CareCoach.com, the company,s unique service that ... caregivers and their physicians. The company will be ... e-Patient Connections; the Hyatt at Bellevue; ...
... YORK, Sept. 20, 2011 Reportlinker.com announces ... available in its catalogue: ... Outlook to 2017 ... Africa Cardiovascular Devices Market Outlook to 2017 ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Middle East and Africa Cardiovascular Devices Market Outlook to 2017 2Middle East and Africa Cardiovascular Devices Market Outlook to 2017 3Middle East and Africa Cardiovascular Devices Market Outlook to 2017 4Middle East and Africa Cardiovascular Devices Market Outlook to 2017 5Middle East and Africa Cardiovascular Devices Market Outlook to 2017 6Middle East and Africa Cardiovascular Devices Market Outlook to 2017 7Middle East and Africa Cardiovascular Devices Market Outlook to 2017 8Middle East and Africa Cardiovascular Devices Market Outlook to 2017 9Middle East and Africa Cardiovascular Devices Market Outlook to 2017 10Middle East and Africa Cardiovascular Devices Market Outlook to 2017 11Middle East and Africa Cardiovascular Devices Market Outlook to 2017 12Middle East and Africa Cardiovascular Devices Market Outlook to 2017 13Middle East and Africa Cardiovascular Devices Market Outlook to 2017 14Middle East and Africa Cardiovascular Devices Market Outlook to 2017 15Middle East and Africa Cardiovascular Devices Market Outlook to 2017 16Middle East and Africa Cardiovascular Devices Market Outlook to 2017 17
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 A ... federal testosterone lawsuits that have been filed by law ... the second week in March, the Firm notes. ... website, parties involved in the federal litigation will meet ... matters related to prescription therapy treatments designed to raise ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... DIY Phishing Kits Make It Easy For Scammers To Steal ... about anyone can get their hands on a DIY phishing ... But it also touched on another important point about ... ways these kits are often implemented, “like compromising legitimate content ...
(Date:2/28/2015)... Aliso Viejo, California (PRWEB) February 28, 2015 ... announced the release of a new overlay plugin for Final ... Pixel Film Studios. , “FCPX Overlay Chromatic gives users total ... X,” said Christina Austin, CEO of Pixel Film Studios. “FCPX ... while maintaining an easy to use interface.” , FCPX Overlay ...
(Date:2/28/2015)... February 28, 2015 Plugin creators from ... Volume 2. A fully customizable transition pack ... Volume 2 gives users total control over 30 transition ... CEO of Pixel Film Studios. “TransFold Volume 2 gives ... , TransFold Volume 2 from Pixel Film Studios brings ...
(Date:2/28/2015)... Vegas, NV (PRWEB) February 28, 2015 My ... will be sending a team to Las Vegas, Nevada for ... Market Week is one of the leading consumer-goods tradeshows and ... vendors at this year’s event. My Shiney Hiney can be ... a fresh, modern design for the at-home personal hygiene brush ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... Consumers Urged To Use Online Quality Information Before Choosing a ... ... Leapfrog Group and the Buyers,Health Care Action Group (BHCAG) today released this ... 1,200,hospitals. Methodist Hospital in St. Louis Park, St. Mary,s Hospital in,Rochester and ...
... Angeles,Area Chamber of Commerce today endorsed Governor Schwarzenegger,s ... payroll fee on employers,with 10 or more employees ... much,to providing health insurance for their employees. The ... and other State,Legislators to use the Governor,s proposal ...
... CHICAGO, Sept. 17 Brookdale Senior Living,Inc. (NYSE: ... has declared a,quarterly cash dividend on its common stock ... 2007. The $0.50 per share dividend is payable,on October ... stock on,September 28, 2007. Brookdale Senior Living Inc. ...
... Takes $1 Million From Insurance Cos, Plans to Force ... Sept. 17 The following,media advisory was issued today ... When: 17th September 2007, 1:30 PM Pacific Standard Time ... Where: Satellite: Galaxy 26 C Band analog @ ...
... 2007 -- A new study by researchers at the University ... for you. , Researchers found that a storyline on ... obesity, hypertension and healthy eating habits had a positive impact ... , The study, published in the Sept. 14 Journal of ...
... public,service announcement is being issued by FMQAI: Helping ... time.,You could be that person. The Every Diabetic Counts ... Health Workers and,conduct a diabetes education program. Call ... place in this free, two and a half-day workshop. ...
Cached Medicine News:Health News:Four Minnesota Hospitals Rate High For Patient Safety and Quality 2Health News:Los Angeles Area Chamber of Commerce Endorses Governor Schwarzenegger's Health Care Proposal 2Health News:ER episode impacts viewers' health knowledge and behavior 2
The ultimate ultrasound system for clinical ophthalmologists....
PremierEdge Stab Knives - 30....
... Technology for the total eye. Whether ... scanning mode or set independently to ... multi-frequency settings are adjustable to accommodate ... transducer for use with tonometer-mounted, hand-held ...
PremierEdge™ MVR Knives. Angled....
Medicine Products: